Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264664 | 0.92 | TNKS (0.36) | TNKSTNKS2KDM5APARP1POLB | |
| SCHEMBL5265367 | 0.88 | POLB (0.33) | TNKSTNKS2PARP1POLBLMNA | |
| SCHEMBL5265378 | 0.80 | POLB (0.33) | TNKSTNKS2POLBLMNATP53 | |
| SCHEMBL5266152 | 0.78 | ALDH1A1 (0.37) | POLBTP53NPSR1 | |
| SCHEMBL5266123 | 0.77 | MEN1 (0.50) | LMNA | |
| SCHEMBL5262020 | 0.76 | LMNA (0.39) | POLBLMNANPSR1 | |
| SCHEMBL5261625 | 0.76 | DCTPP1 (0.35) | TNKSTNKS2POLBLMNAKCNH2 | |
| SCHEMBL5263885 | 0.75 | DCTPP1 (0.36) | TNKSTNKS2POLBLMNAKCNH2 | |
| SCHEMBL5265799 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL5263197 | 0.75 | CFD (0.43) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | TNKS 4052/4885TNKS2 4417/4885KDM5A 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.